Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
Researchers from San Diego-based ViaCyte and UC San Diego provided new details about the first-ever human clinical trial of a stem cell-derived therapy for patients with type 1 diabetes yesterday at a scientific symposium at The Salk Institute.
The early stage clinical trial is intended to test the safety of an approach that ViaCyte has spent over 12 years developing, according to Kevin D’Armour, ViaCyte’s chief scientific officer.
The approach, called islet replacement therapy, implants a semi-permeable packet containing human embryonic stem cells just under the skin of patients with type 1 diabetes. ViaCyte has engineered the stem cells to grow into healthy pancreatic cells that produce insulin and other hormones used to maintain normal levels of blood sugar.
http://www.xconomy.com/san-diego/20...lanting-first-stem-cell-therapy-for-diabetes/
The early stage clinical trial is intended to test the safety of an approach that ViaCyte has spent over 12 years developing, according to Kevin D’Armour, ViaCyte’s chief scientific officer.
The approach, called islet replacement therapy, implants a semi-permeable packet containing human embryonic stem cells just under the skin of patients with type 1 diabetes. ViaCyte has engineered the stem cells to grow into healthy pancreatic cells that produce insulin and other hormones used to maintain normal levels of blood sugar.
http://www.xconomy.com/san-diego/20...lanting-first-stem-cell-therapy-for-diabetes/